Bliss GVS Pharma (BLISSGVS-BE) Share Price Falls 5% Today
- September 29, 2026
- Posted by: Harsh Piplani
- Category: News
Bliss GVS Pharma Share Price fell sharply in today’s session, with the stock closing at Rs 700.75 after a 5% decline. The company’s market capitalisation stands at Rs 7,542.02 Cr, placing it in the Mid Cap category. Bliss GVS Pharma Share Price Today therefore reflects a clear one-day price fall rather than a change in the company’s longer-term business profile. The data supplied for this move confirms the price event, but it does not establish a company-specific catalyst. For readers tracking Bliss GVS Pharma Stock News, the key point is that today’s trade reset the share price from Rs 737.60 to Rs 700.75. In this Univest note, we focus on the verified price action, the company’s valuation metrics, its Healthcare sector context and how its numbers compare with listed pharmaceutical peers.
Bliss GVS Pharma Share Price also matters for investors following Bliss GVS Pharma Share Price Today because the move came after an open at Rs 730.00 and a session high of Rs 730.00, while the low matched the closing price at Rs 700.75. That combination shows that the stock spent the day below its opening level and ended at the lowest point of the session. The exact turnover was Rs 3.45 Cr. Below, Univest breaks down what the decline shows, what the numbers say about Bliss GVS Pharma Stock Performance, and which verified fundamentals deserve attention next.
Bliss GVS Pharma (BLISSGVS-BE) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 700.75 |
| Previous Close | Rs 737.6 |
| Today's Move | -Rs 36.85 (-5%) |
| Open | Rs 730 |
| High | Rs 730 |
| Low | Rs 700.75 |
| Turnover | Rs 3.45 crore |
| Market Capitalisation | Rs 7,542.02 crore |
| Market Cap Category | Mid Cap |
Bliss GVS Pharma Share Price Today reflects a clean one-session decline of Rs 36.85, or 5%, from the previous close of Rs 737.60 to Rs 700.75. The stock opened at Rs 730.00, touched an intraday high of Rs 730.00 and then moved to an intraday low of Rs 700.75, which was also the closing price. That pattern confirms that today’s price action stayed below the opening level and finished at the day’s low. The exact turnover was Rs 3.45 Cr, a factual traded-value figure that does not, by itself, explain the move.
Bliss GVS Pharma (BLISSGVS-BE) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 7,542.02 crore |
| P/E Ratio | 57.59x |
| P/B Ratio | 6.36x |
| ROE | 12.11% |
| ROCE | 17.4% |
| EPS | Rs 12.81 |
| Book Value Per Share | Rs 115.94 |
| Dividend Yield | 0.2% |
Profitability metrics are mixed but constructive in absolute terms. ROE is 12.11% and ROCE is 17.4%, both of which are useful indicators of capital efficiency. In a fundamental analysis lens, the company’s EPS of Rs 12.81 indicates earnings attributable to each share, while book value of Rs 115.94 shows the accounting net worth behind each share. The dividend yield of 0.2% is a historical/current payout measure, not a guarantee of future distribution. For readers comparing Bliss GVS Pharma Stock News with other pharmaceutical counters, the main takeaway is that today’s fall occurred despite metrics that remain established in the public data set. The next section of Univest moves from company-level numbers to industry positioning.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 57.59x |
| Benchmark Median P/E | 32.59x |
| Benchmark Average P/E | 49x |
| Benchmark P/E Range | 3.46x to 707.31x |
| Company P/B Ratio | 6.36x |
| Benchmark Median P/B | 2.88x |
| Benchmark Average P/B | 4.34x |
| Company ROE | 12.11% |
| Benchmark Median ROE | 11.7% |
| Benchmark Average ROE | 10.68% |
| Company ROCE | 17.4% |
| Benchmark Median ROCE | 13.61% |
| Benchmark Average ROCE | 13.4% |
| Company Market Capitalisation | Rs 7,542.02 crore |
| Benchmark Median Market Cap | Rs 783.26 crore |
| Benchmark Average Market Cap | Rs 14,389.26 crore |
Bliss GVS Pharma operates in Healthcare, specifically Pharmaceuticals & Drugs, and its valuation should be read against the same-industry benchmark set of 199 companies. The company’s P/E of 57.59 is above the benchmark median of 32.59 and above the benchmark average of 49.00. Its P/B of 6.36 is also above the benchmark median of 2.88 and the benchmark average of 4.34. On profitability, Bliss GVS Pharma’s ROE of 12.11% is slightly above the benchmark median of 11.70%, while ROCE of 17.4% is above the benchmark median of 13.61% and the benchmark average of 13.40%.
The sector data also shows that the industry’s market capitalisation median is Rs 783.26 Cr and the average is Rs 14,389.26 Cr across the 199-company scope. Bliss GVS Pharma’s Rs 7,542.02 Cr market cap sits above the sector median and below the sector average. That makes the stock a meaningful mid-sized pharmaceutical company within its peer set. For Bliss GVS Pharma Share Price, the sector context matters because the company trades at a higher P/E and P/B than the benchmark, while ROE and ROCE remain above the median. Univest notes this as a valuation comparison, not a forecast. The next section compares the stock with listed peers using the same disclosed metrics.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,44,716.74 | 36.5 | 5.1 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,55,115.31 | 86.51 | 14.33 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,89,613.38 | 84.92 | 20.64 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,19,899.96 | 26.79 | 4.48 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,12,875.68 | 33.29 | 3.19 | 11.83 | 16 |
Bliss GVS Pharma Share Price can be better understood when set beside selected listed pharmaceutical peers. The company’s P/E of 57.59 is higher than Sun Pharmaceutical Industries at 36.50, Cipla at 33.29 and Zydus Lifesciences at 26.79, but lower than Divi’s Laboratories at 86.51 and Torrent Pharmaceuticals at 84.92. This places Bliss GVS Pharma in the upper part of the peer valuation band, though not at the highest end of the group.
On profitability, Bliss GVS Pharma’s ROE of 12.11% is below Zydus Lifesciences at 19.69%, Divi’s Laboratories at 16.19%, Torrent Pharmaceuticals at 26.76% and Lupin at 27.11%, but close to Cipla at 11.83% and Sun Pharma at 14.85%. Its ROCE of 17.4% is above Cipla at 16.00% and Sun Pharma at 19.11% is slightly higher, while Divi’s Laboratories at 21.51%, Torrent Pharmaceuticals at 19.27%, Zydus Lifesciences at 21.39% and Lupin at 28.86% stand higher. Market cap-wise, Bliss GVS Pharma at Rs 7,542.02 Cr is smaller than all the listed peers in this comparison set.
Why Investors Are Watching Bliss GVS Pharma
- Bliss GVS Pharma Share Price fell 5% today to Rs 700.75 from Rs 737.60.
- The stock opened at Rs 730.00, hit a high of Rs 730.00 and closed at Rs 700.75.
- Market capitalisation is Rs 7,542.02 Cr, which places the company in the Mid Cap category.
- P/E is 57.59, P/B is 6.36, ROE is 12.11% and ROCE is 17.4%.
- Against the same-industry benchmark, Bliss GVS Pharma trades above the median P/E and P/B.
About Bliss GVS Pharma
Bliss GVS Pharma is part of the Healthcare sector and the Pharmaceuticals & Drugs industry. The company’s latest market data shows a market capitalisation of Rs 7,542.02 Cr, with a listed share price that moved down today. For investors scanning Bliss GVS Pharma Company News, the most relevant fact pattern is the combination of a one-day decline, a mid-cap market value and valuation multiples that remain above the industry benchmark. Univest tracks such company-level updates so readers can place Bliss GVS Pharma Share News in the context of sector data and peer comparison.
Track Bliss GVS Pharma Share Price on Univest
Use Bliss GVS Pharma (BLISSGVS-BE) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.
Track Bliss GVS Pharma Share Price on Univest for live share price updates, fundamental ratios, shareholding pattern, 52-week levels and market insights. Univest also presents company news, valuation context and sector comparisons in one place so you can follow Bliss GVS Pharma Stock News with verified data.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Bliss GVS Pharma Share Price fall today?
Ans. The supplied data confirms that Bliss GVS Pharma Share Price fell 5% today, but it does not establish a company-specific catalyst. The stock closed at Rs 700.75 after ending below its opening level.
What is Bliss GVS Pharma Share Price today?
Ans. Bliss GVS Pharma Share Price today is Rs 700.75. It declined Rs 36.85, or 5%, from the previous close of Rs 737.60 and finished at the day’s low. The previous close was Rs 737.6.
What is Bliss GVS Pharma market capitalisation?
Ans. Bliss GVS Pharma market capitalisation is Rs 7,542.02 Cr. The company is classified as Mid Cap in the supplied data, which provides company-size context for the share price movement. The company operates in the Healthcare sector.
How is Bliss GVS Pharma valued on P/E and P/B?
Ans. Bliss GVS Pharma trades at a P/E of 57.59 and a P/B of 6.36. Both are above the same-industry benchmark median, which helps frame the stock’s current valuation. The company trades at a P/E ratio of 57.59x.
How do ROE and ROCE look for Bliss GVS Pharma?
Ans. Bliss GVS Pharma reports ROE of 12.11% and ROCE of 17.4%. Both measures are above the industry benchmark median, showing the company’s capital returns in the latest data set. ROE stands at 12.11%.
How does Bliss GVS Pharma compare with peers?
Ans. Bliss GVS Pharma’s market cap of Rs 7,542.02 Cr is below the listed peer group shown in the data. Its P/E is below Divi’s and Torrent, but above Sun Pharma, Cipla and Zydus.
